Adelöw C, Ahlbom A, Feychting M, Johnsson F, Schwartzbaum J, Tomson T
Department of Neurology, Karolinska University Hospital, Solna, Stockholm, Sweden.
J Neurol Neurosurg Psychiatry. 2006 Jun;77(6):784-6. doi: 10.1136/jnnp.2005.083931.
Epilepsy and long term use of antiepileptic drugs have been suggested to be associated with an increased risk of cancer. The authors therefore set out to analyse previous diagnosis of epilepsy as a risk factor for certain cancer forms in a case control study.
Incident cases of leukaemia, lymphoma, myeloma, and pancreatic cancer were identified from the Swedish Cancer Registry 1987-99, a total of 52 861 cases. Controls (n = 137 485) were randomly selected from the Swedish Population Registry stratified on age, sex, and year of cancer diagnosis. Cases and controls were linked to the Swedish Hospital Discharge Registry for 1969-99 to identify individuals with first time hospital discharge for epilepsy.
While an epilepsy diagnosis the same year as a cancer diagnosis carried an increased risk of non-Hodgkin's lymphoma (OR = 2.89, 95% CI 1.89 to 4.41), Hodgkin's disease (OR = 4.77, 95% CI 1.77 to 13.30), leukaemia (OR = 2.55, 95% CI 1.50 to 4.32), acute myeloid leukaemia (OR = 3.65, 95% CI 1.68 to 7.93), and pancreatic cancer (OR = 2.05, 95% CI 1.22 to 3.45), the authors found no support for an association between discharge with a diagnosis of epilepsy two years or more before the diagnosis of cancer and an increased risk of any of the types of cancer included in this analysis. The lack of association was also evident for individuals with an epilepsy diagnosis preceding malignancy/reference year by >10 years.
Clinical examinations prompted by seizure onset probably mainly explain the observed association between epilepsy diagnoses the year before a cancer diagnosis. However, these results lend no support to the suggestion that epilepsy, and presumably long term exposure to antiepileptic drugs, is associated with an increased risk of the types of cancer included in the present study.
有研究表明癫痫及长期使用抗癫痫药物与癌症风险增加有关。因此,作者开展了一项病例对照研究,分析既往癫痫诊断作为某些癌症类型风险因素的情况。
从瑞典癌症登记处(1987 - 1999年)确定白血病、淋巴瘤、骨髓瘤和胰腺癌的新发病例,共52861例。对照(n = 137485)从瑞典人口登记处按年龄、性别和癌症诊断年份分层随机选取。病例和对照与1969 - 1999年瑞典医院出院登记处进行关联,以确定首次因癫痫出院的个体。
与癌症诊断同年的癫痫诊断会增加非霍奇金淋巴瘤(比值比[OR] = 2.89,95%置信区间[CI] 1.89至4.41)、霍奇金病(OR = 4.77,95% CI 1.77至13.30)、白血病(OR = 2.55,95% CI 1.50至4.32)、急性髓细胞白血病(OR = 3.65,95% CI 1.68至7.93)和胰腺癌(OR = 2.05,95% CI 1.22至3.45)的发病风险,但作者发现癌症诊断前两年或更长时间因癫痫诊断出院与本分析中任何一种癌症类型风险增加之间没有关联。对于在恶性肿瘤/参考年份前10年以上诊断为癫痫的个体,这种缺乏关联的情况也很明显。
癫痫发作引发的临床检查可能主要解释了癌症诊断前一年癫痫诊断之间观察到的关联。然而,这些结果不支持癫痫以及可能长期接触抗癫痫药物与本研究中所包括的癌症类型风险增加有关的观点。